Treatment Considerations for Depression in the Elderly

CNS Spectrums

Volumn 8, Issue 12 SUPPL. 3, 2003, Pages 14-19

  Dunner, David L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P ANTAGONIST; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGED; AGING; BEHAVIOR THERAPY; CHRONIC DISEASE; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DIZZINESS; DRUG CROSS REACTIVITY; ELDERLY CARE; ELECTROCONVULSIVE THERAPY; HUMAN; INSOMNIA; LIVER TOXICITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIAPISM; PRIORITY JOURNAL; PROBLEM SOLVING; RECURRENT DISEASE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL MODEL; TACHYCARDIA; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 1642460957     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900008233     Document Type: Review

References (56)

1. Alexopoulos GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med. October 2001:1-86. Special Report.
2. Krishnan KRR, Hays JC, Tupler LA, et al. Clinical and phenomenological comparisons of late-onset and early-onset depression. Am J Psychiatry. 1995;152:785-788.
3. Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County Study. Arch Gen Psychiatry. 2000;57:601-607.
4. Luber MP, Meyers BS, Williams-Russo PG, et al. Depression and service utilization in elderly primary care patients. Am J Geriatr Psychiatry. 2001;9:169-176.
5. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Lenze EJ. Comorbidity of depression and anxiety in the elderly. Curr Psychiatry Rep. 2003;5:62-67.
7. Alexopoulos GS, Borson S, Cuthbert BM, et al. Assessment of late life depression. Biol Psychiatry. 2002;52;164-174.
8. Conwell Y, Duberstein PR, Caine ED. Risk factors for suicide in late life. Biol Psychiatry. 2002;52:193-204.
9. Hirschfeld RMA, Russell JM. Assessment and treatment of suicidal patients. N Eng J Med. 1997;337:910-915.
10. Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry. 2003;60:610-617.
11. Krishnan KRR. Biological risk factors in late depression. Biol Psychiatry. 2002;52:185-192.
12. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, psychopathology, and biological treatment. Biol Psychiatry. 2002;52:253-264.
13. Devanand DP. Comorbid psychiatric disorders in late life depression. Biol Psychiatry. 2002;52:236-242.
14. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501.
15. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-359.
16. Alexopoulos GS, Kiosses DN, Choi SJ, et al. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. AmJ Psychiatry. 2002;159:1929-1932.
17. Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors in depression treatment outcome in later life. Am J Psychiatry. 2002;10:592-598.
18. Salloway S, Boyle PA, Correia S, et al. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed out-patients. Am J Psychiatry. 2002;10:107-111.
19. Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry. 2002;52:175-184.
20. Arean PA, Cook BL. Psychotherapy and combined psychotherapy/pharmacology for late life depression. Biol Psychiatry. 2002;52:293-303.
21. Gallagher-Thompson D, Hanley-Peterson P, Thompson LW. Maintenance of gains versus relapse following brief psychotherapy for depression. J Consult Clin Psychol. 1990;58:371-374.
22. Reynolds CF, III, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39-45.
23. Lenze EJ, Dew MA, Mazumdar S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects of social adjustment. Am J Psychiatry. 2002;159:466-468.
24. Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836-2845.
25. Salzman C, Wong E, Wright BC. Drug and ECT treatment of depression in the elderly, 1996-2001: a literature review. Biol Psychiatry. 2002;52:265-284.
26. Kirby D, Harrigan S, Ames D. Hyponatremia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatric Psychiatry. 2002;17:231-237.
27. Heiligenstein JH, Ware JE, Buesterien KM, et al. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr. 1995;7(suppl):125-137.
28. Small GW, Hamilton SH, Bystritsky A, et al. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr. 1995;7(suppl):41-53.
29. Koran LM, Hamilton SH, Hertzman M, et al. Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1995;15:421-427.
30. Arranz FJ, Ros S. Effects of comorbidity and polypharmacy in the clinical usefulness of sertraline in elderly depressed patients: an open multicenter study. J Affect Disor. 1997;46:285-291.
31. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multi-center, parallel group, double-blind, placebo-controlled study of sertraline in elderly patients with major depression. Am J Psychiatry. 2003;160:1277-1285.
32. Bump GM, Mulsant BH, Pollock MG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13:38-44.
33. Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6 week outcome. J Clin Psychiatry. 1999;60(suppl 20):16-20.
34. Dunner DL, Cohn JB, Walshe T III, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992;53(suppl):57-60.
35. Reynolds CF III. Paroxetine treatment of depression of late life. Psychopharm Bull. 2003;37(suppl):123-134.
36. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64:1065-1074.
37. Karlsson I, Godderis K, De Mendonca A, Lima C. A randomized, double-blind comparison of the efficacy and safety of citalopram combined with mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Clin Psychiatry. 2000;15:295-305.
38. Kyle CJ, Peterson HEH, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety. 1998;8:147-153.
39. Altamura AC, Mauri MC, Rudas N, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(suppl 1):S25-S37.
40. Scher M, Krieger JN, Juergens S.Trazodone and priapism. Am J Psychiatry. 1983;140:1362-1363.
41. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000;61:196-202.
42. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry. 2001;16:862-865.
43. Wellbutrin (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2001.
44. Amore M, Ricci M, Zanardi R, et al. Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord. 1997;46:293-296.
45. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry. 1996;8:169-178.
46. Khan A, Rudolph R, Baumel B, et al. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharm Bull. 1995;31:753-758.
47. Mahaptra SN. A randomized, double-blind, parallel group comparison of venlafaxine and dothiepin in geriatric patients with major depression. IJPC. 1997;51:209-213.
48. Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety. 2000;12(suppl 1):63-68.
49. Goldberg RJ. Antidepressant use in the elderly: current status of nefazodone, venlafaxine, and moclobemide. Drugs Aging. 1997;11:119-131.
50. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
51. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. NEJM. 2000;342:1462-1470.
52. Dunner DL, Laird LK. Comparative safety and tolerability of nefazodone. J Clin Psychiatry. 2003;63(suppl 1):33-36.
53. Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multi-center comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93:184-190.
54. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10:541-550.
55. Abrams R. Electroconvulsive Therapy. 4th ed. New York, NY: Oxford Press; 2002.
56. Small JG, Kellams JJ, Milstein, et al. Complications with electroconvulsive treatment combined with lithium. Biol Psychiatry. 1980;15:103-112.